Filing Details

Accession Number:
0000950170-24-010798
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-02 19:03:43
Reporting Period:
2024-01-30
Accepted Time:
2024-02-02 19:03:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1786255 Icosavax Inc. ICVX Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1873839 K. Adam Simpson C/O Icosavax, Inc.
1930 Boren Ave., Suite 1000
Seattle WA 98101
Chief Executive Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-02-01 6,532 $0.00 525,044 No 4 G Indirect By family trust
Common Stock Acquisiton 2024-02-01 15,000 $1.04 373,657 No 4 M Direct
Common Stock Disposition 2024-02-01 15,000 $15.29 358,657 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 G Indirect By family trust
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-02-01 15,000 $0.00 15,000 $1.04
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
191,449 2031-01-28 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 129,032 Indirect By family trust
Common Stock 129,032 Indirect By family trust
Footnotes
  1. The sales were effected pursuant to a Rule 10b5-1 instruction letter dated September 16, 2023.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.31. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. 25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.